Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia

Atherosclerosis

Volumn 130, Issue 1-2, 1997, Pages 191-197

  Bertolini, Stefano ^a   Bon, Gabriele Bittolo ^b   Campbell, L Malcolm ^c   Farnier, Michel ^d   Langan, John ^e   Mahla, Gerhard ^f   Pauciullo, Paolo ^g   Sirtori, Cesare ^h   Egros, Fabrice ⁱ   Fayyad, Rana ^j   Nawrocki, James W ^j  

^a UNIVERSITY OF GENOA   (Italy)

^b Osp Civ Riun   (Italy)

^c Southbank Surgery   (United Kingdom)

^d Point Medical   (France)

^e Baillieston Health Centre   (United Kingdom)

^f University of Naples ^*  (Germany)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h UNIVERSITY OF MILAN   (Italy)

ⁱ Parke Davis GmbH Berlin   (Germany)

^j PFIZER INC   (United States)

more..

Author keywords

atorvastatin; HMGRI; hypercholesterolemia; LDL C; pravastatin

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN; PLACEBO; PRAVASTATIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRAVASTATIN; PYRROLES; TRIGLYCERIDES;

EID: 18544412108     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)06052-2     Document Type: Article

References (18)

1. Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham Study. JAMA 1987;257:2176-2180.
2. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36-39.
3. Brown BG, Albers JJ, Fisher LD, Schaefer SM, Jiin-Tarng L, Kaplan C, Zhao XQ, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med 1990;323(19):1289-1298.
4. Buchwald H, Vargo RL, Matts JP, Long JM, Fitch LL, Campbell GS, Pearce MB, Yellin AE, Edmiston WA, Smink RD Jr, et al. Effect of partial ilial bypass on mortality and morbidity from coronary artery disease in patients with hypercholesterolemia-Report of the Program on Surgical Control of the Hyperlipidemia (POSCH). New Engl J Med 1990;323:946.
5. Watts GF, Lewis B, Brunt NH,Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine, in the St. Thomas' atherosclerosis regression study (STARS). Lancet 1992;339:563-569.
6. Blankenhorn DH, Nessin SA, Johnson RL, Sanmarco ME, Azin SP, Cashin-Hemphill L. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary bypass grafts. JAMA 1987;257:3233-3240.
7. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrick RF, Battaglini JW, Moriarty DJ, et al. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI type II coronary intervention study. Circulation 1984;69:313-324.
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333(20):1301-1307.
9. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
10. Lipid Research Clinics Program: The lipid research clinics coronary primary prevention trial results: 1. reduction in incidence of coronary artery disease. JAMA 1984;251:351-564.
11. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, Maenpaa H, Malkonen M, Manttari M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjoblom T, Nikkila EA. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med 1987;317:1237-1245.
12. European Atherosclerosis Society. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr Metab Cardiovasc Dis 1992;2:113-156.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
14. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien PJ, Jones PH, Haber HE, Black D. Reduction of LDL-cholesterol by 25 to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vase Biol 1995;15:678-682.
15. Bakker-Arkema R, Davidson M, Goldstein R, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown V, Miller VT, Shurzinske LJ, Black D. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275(2):128-133.
16. Lambrecht LJ, Malini PL and the European Study Group. Efficacy and tolerability of simvastatin 20 mg versus pravastatin 20 mg in patients with primary hypercholesterolemia. Acta Cardiol 1993;XVLIX(6):541-554.
17. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18(6):499-502.
18. The Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvasatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71:1408-1414.